More than 560 meds in pipeline for rare diseases, US report states

9 May 2016

There are more than 560 novel treatments in development to treat the 30 million Americans currently living with a rare disease that has few or no treatment options, according to a new report.

Pharmaceutical Research and Manufacturers of America (PhRMA), the trade group representing pharma companies in the USA, published the findings in its report entitled Medicines in Development for Rare Diseases.

The report analyses 7,000 known rare diseases – which are classified as those affecting fewer than 200,000 people in the USA – and finds that, due to advances in science, there is now promise for brighter futures for American patients and families.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK